Emergent BioSolutions (EBS) Tops Q3 EPS by 31c

Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $1.21, $0.31 better than the analyst estimate of $0.90. Revenue for the quarter came in at $311.8 million versus the consensus estimate of $289.27 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery